Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
AMN vs MMS vs DOCS vs CACI vs HIMS
Revenue, margins, valuation, and 5-year total return — side by side.
Specialty Business Services
Medical - Healthcare Information Services
Information Technology Services
Medical - Equipment & Services
AMN vs MMS vs DOCS vs CACI vs HIMS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Specialty Business Services | Medical - Healthcare Information Services | Information Technology Services | Medical - Equipment & Services |
| Market Cap | $869M | $3.64B | $5.24B | $10.82B | $6.63B |
| Revenue (TTM) | $3.42B | $5.32B | $638M | $9.16B | $2.35B |
| Net Income (TTM) | $-32M | $373M | $239M | $537M | $128M |
| Gross Margin | 25.5% | 24.6% | 89.7% | 14.9% | 69.7% |
| Operating Margin | 0.3% | 10.8% | 37.4% | 9.3% | 4.6% |
| Forward P/E | 11.0x | 7.8x | 16.8x | 17.4x | 51.5x |
| Total Debt | $803M | $1.44B | $12M | $3.34B | $1.12B |
| Cash & Equiv. | $34M | $260M | $210M | $106M | $229M |
AMN vs MMS vs DOCS vs CACI vs HIMS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| AMN Healthcare Serv… (AMN) | 100 | 23.2 | -76.8% |
| Maximus, Inc. (MMS) | 100 | 74.6 | -25.4% |
| Doximity, Inc. (DOCS) | 100 | 42.0 | -58.0% |
| CACI International … (CACI) | 100 | 203.6 | +103.6% |
| Hims & Hers Health,… (HIMS) | 100 | 249.5 | +149.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AMN vs MMS vs DOCS vs CACI vs HIMS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AMN ranks third and is worth considering specifically for momentum.
- +14.6% vs DOCS's -55.4%
MMS has the current edge in this matchup, primarily because of its strength in value and dividends.
- Lower P/E (7.8x vs 51.5x)
- 1.8% yield; 2-year raise streak; the other 4 pay no meaningful dividend
DOCS is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 20.0%, EPS growth 54.2%, 3Y rev CAGR 18.4%
- Lower volatility, beta 1.03, Low D/E 1.1%, current ratio 6.97x
- PEG 0.21 vs CACI's 1.44
- Beta 1.03, current ratio 6.97x
CACI is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.30
- 416.4% 10Y total return vs HIMS's 161.9%
- Beta 0.30 vs HIMS's 2.40, lower leverage
HIMS is the clearest fit if your priority is growth.
- 59.0% revenue growth vs AMN's -8.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs AMN's -8.5% | |
| Value | Lower P/E (7.8x vs 51.5x) | |
| Quality / Margins | 37.5% margin vs AMN's -0.9% | |
| Stability / Safety | Beta 0.30 vs HIMS's 2.40, lower leverage | |
| Dividends | 1.8% yield; 2-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +14.6% vs DOCS's -55.4% | |
| Efficiency (ROA) | 20.7% ROA vs AMN's -1.4%, ROIC 20.0% vs 1.6% |
AMN vs MMS vs DOCS vs CACI vs HIMS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
AMN vs MMS vs DOCS vs CACI vs HIMS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DOCS leads in 2 of 6 categories
AMN leads 1 • HIMS leads 1 • MMS leads 0 • CACI leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CACI is the larger business by revenue, generating $9.2B annually — 14.4x DOCS's $638M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to AMN's -0.9%. On growth, AMN holds the edge at +99.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.4B | $5.3B | $638M | $9.2B | $2.3B |
| EBITDAEarnings before interest/tax | $127M | $645M | $250M | $1.1B | $164M |
| Net IncomeAfter-tax profit | -$32M | $373M | $239M | $537M | $128M |
| Free Cash FlowCash after capex | $714M | $372M | $314M | $470M | $73M |
| Gross MarginGross profit ÷ Revenue | +25.5% | +24.6% | +89.7% | +14.9% | +69.7% |
| Operating MarginEBIT ÷ Revenue | +0.3% | +10.8% | +37.4% | +9.3% | +4.6% |
| Net MarginNet income ÷ Revenue | -0.9% | +7.0% | +37.5% | +5.9% | +5.5% |
| FCF MarginFCF ÷ Revenue | +20.9% | +7.0% | +49.2% | +5.1% | +3.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +99.9% | -4.1% | +9.8% | +8.5% | +28.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +56.8% | +6.5% | -16.2% | +17.8% | -27.3% |
Valuation Metrics
AMN leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 12.1x trailing earnings, MMS trades at a 76% valuation discount to HIMS's 50.3x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.30x vs CACI's 1.81x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $869M | $3.6B | $5.2B | $10.8B | $6.6B |
| Enterprise ValueMkt cap + debt − cash | $1.6B | $4.8B | $5.0B | $14.1B | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | -9.06x | 12.10x | 23.45x | 21.95x | 50.32x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.05x | 7.83x | 16.83x | 17.37x | 51.51x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.19x | 0.30x | 1.81x | — |
| EV / EBITDAEnterprise value multiple | 8.63x | 6.67x | 21.14x | 14.65x | 42.68x |
| Price / SalesMarket cap ÷ Revenue | 0.32x | 0.67x | 9.18x | 1.25x | 2.82x |
| Price / BookPrice ÷ Book value/share | 1.35x | 2.31x | 4.84x | 2.82x | 12.25x |
| Price / FCFMarket cap ÷ FCF | 3.72x | 9.93x | 19.64x | 22.48x | 89.61x |
Profitability & Efficiency
DOCS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-5 for AMN. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs HIMS's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.0% | +21.8% | +24.4% | +13.1% | +23.7% |
| ROA (TTM)Return on assets | -1.4% | +8.8% | +20.7% | +5.7% | +6.0% |
| ROICReturn on invested capital | +1.6% | +15.1% | +20.0% | +9.2% | +10.7% |
| ROCEReturn on capital employed | +2.0% | +17.4% | +22.3% | +11.6% | +10.9% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 8 | 9 | 7 | 4 |
| Debt / EquityFinancial leverage | 1.25x | 0.86x | 0.01x | 0.86x | 2.07x |
| Net DebtTotal debt minus cash | $769M | $1.2B | -$197M | $3.2B | $892M |
| Cash & Equiv.Liquid assets | $34M | $260M | $210M | $106M | $229M |
| Total DebtShort + long-term debt | $803M | $1.4B | $12M | $3.3B | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | -1.70x | 4.93x | — | 4.52x | — |
Total Returns (Dividends Reinvested)
HIMS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $2,488 for AMN. Over the past 12 months, AMN leads with a +14.6% total return vs DOCS's -55.4%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs AMN's -37.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +48.7% | -22.5% | -39.9% | -8.8% | -23.2% |
| 1-Year ReturnPast 12 months | +14.6% | +1.1% | -55.4% | +3.3% | -51.0% |
| 3-Year ReturnCumulative with dividends | -75.1% | -11.6% | -24.2% | +61.2% | +116.6% |
| 5-Year ReturnCumulative with dividends | -75.1% | -20.4% | -50.9% | +85.4% | +137.6% |
| 10-Year ReturnCumulative with dividends | -41.5% | +39.7% | -50.9% | +416.4% | +161.9% |
| CAGR (3Y)Annualised 3-year return | -37.1% | -4.0% | -8.8% | +17.3% | +29.4% |
Risk & Volatility
Evenly matched — AMN and CACI each lead in 1 of 2 comparable metrics.
Risk & Volatility
CACI is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMN currently trades 94.7% from its 52-week high vs DOCS's 34.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 0.72x | 1.03x | 0.30x | 2.40x |
| 52-Week HighHighest price in past year | $23.74 | $100.00 | $76.51 | $683.50 | $70.43 |
| 52-Week LowLowest price in past year | $14.87 | $60.75 | $20.55 | $409.62 | $13.74 |
| % of 52W HighCurrent price vs 52-week peak | +94.7% | +66.7% | +34.0% | +71.7% | +36.4% |
| RSI (14)Momentum oscillator 0–100 | 57.2 | 35.0 | 60.1 | 36.4 | 54.5 |
| Avg Volume (50D)Average daily shares traded | 849K | 683K | 2.7M | 270K | 34.9M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AMN as "Buy", MMS as "Buy", DOCS as "Buy", CACI as "Buy", HIMS as "Hold". Consensus price targets imply 65.0% upside for MMS (target: $110) vs 0.1% for AMN (target: $23). MMS is the only dividend payer here at 1.78% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $22.50 | $110.00 | $42.79 | $725.50 | $29.67 |
| # AnalystsCovering analysts | 17 | 16 | 22 | 29 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | +1.8% | — | — | — |
| Dividend StreakConsecutive years of raises | — | 2 | — | — | — |
| Dividend / ShareAnnual DPS | — | $1.19 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | +12.3% | +2.3% | +1.6% | +1.4% |
DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMN leads in 1 (Valuation Metrics). 1 tied.
AMN vs MMS vs DOCS vs CACI vs HIMS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AMN or MMS or DOCS or CACI or HIMS a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -8. 5% for AMN Healthcare Services, Inc. (AMN). Maximus, Inc. (MMS) offers the better valuation at 12. 1x trailing P/E (7. 8x forward), making it the more compelling value choice. Analysts rate AMN Healthcare Services, Inc. (AMN) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AMN or MMS or DOCS or CACI or HIMS?
On trailing P/E, Maximus, Inc.
(MMS) is the cheapest at 12. 1x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Maximus, Inc. is actually cheaper at 7. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 21x versus CACI International Inc's 1. 44x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — AMN or MMS or DOCS or CACI or HIMS?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -75. 1% for AMN Healthcare Services, Inc. (AMN). Over 10 years, the gap is even starker: CACI returned +416. 4% versus DOCS's -50. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AMN or MMS or DOCS or CACI or HIMS?
By beta (market sensitivity over 5 years), CACI International Inc (CACI) is the lower-risk stock at 0.
30β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 708% more volatile than CACI relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AMN or MMS or DOCS or CACI or HIMS?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -8. 5% for AMN Healthcare Services, Inc. (AMN). On earnings-per-share growth, the picture is similar: Doximity, Inc. grew EPS 54. 2% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AMN or MMS or DOCS or CACI or HIMS?
Doximity, Inc.
(DOCS) is the more profitable company, earning 39. 1% net margin versus -3. 5% for AMN Healthcare Services, Inc. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus 1. 2% for AMN. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AMN or MMS or DOCS or CACI or HIMS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 21x versus CACI International Inc's 1. 44x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Maximus, Inc. (MMS) trades at 7. 8x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 43. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MMS: 65. 0% to $110. 00.
08Which pays a better dividend — AMN or MMS or DOCS or CACI or HIMS?
In this comparison, MMS (1.
8% yield) pays a dividend. AMN, DOCS, CACI, HIMS do not pay a meaningful dividend and should not be held primarily for income.
09Is AMN or MMS or DOCS or CACI or HIMS better for a retirement portfolio?
For long-horizon retirement investors, CACI International Inc (CACI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
30), +416. 4% 10Y return). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CACI: +416. 4%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AMN and MMS and DOCS and CACI and HIMS?
These companies operate in different sectors (AMN (Healthcare) and MMS (Industrials) and DOCS (Healthcare) and CACI (Technology) and HIMS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: AMN is a small-cap quality compounder stock; MMS is a small-cap deep-value stock; DOCS is a small-cap high-growth stock; CACI is a mid-cap quality compounder stock; HIMS is a small-cap high-growth stock. MMS pays a dividend while AMN, DOCS, CACI, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.